REGN Q4 Earnings Beat Estimates, Sales Rise on Eylea HD Growth

Key Takeaways Regeneron posted Q4 EPS of $11.44, beating estimates, while revenues rose 3% to $3.9 billion.REGN saw Eylea HD sales jump 66%, offsetting sharp declines in U.S. sales of its legacy Eylea drug.Higher R&D and manufacturing investments pressured margins, contributing to a 5% year-over-year EPS drop.Regeneron Pharmaceuticals, Inc. (REGN) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $11.44, which comfortably beat the Zacks Consensus Estimate of $10.56. However, the bottom line ...